Share This

PR Newswire Asia's news > Infectious Disease Control

 |   Title only   |   Print    Next page > 
     
Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) ...
2024-05-08T    Infectious Disease Control 
INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global Defense Against Potential Future Pandemics
Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations ...
2024-04-29T    Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
SHANGHAI , April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year on April 25 . World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight ...
2024-04-26T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
"Aiming to offer a Dengue antiviral treatment course in $100 price range" Hyundai Bioscience decides to conduct dengue clinical trials in Brazil , which has the largest number of Dengue ...
2024-04-25T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19
Legacy coronavirus biochemistry was overlooked that governs spike protein toxicity, key morbidities, risk factors and therapeutic responses ...
2024-04-22T    Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea , April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com ) announced on April 15 that it would carry ...
2024-04-19T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea , April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com ) announced on April 15 that it would carry ...
2024-04-19T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — ...
2024-04-17T    Computer/Electronics   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — ...
2024-04-17T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant -- ...
2024-04-15T    Health Care/Hospital   Infectious Disease Control 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.